CAJ | 학술논문

目的：研究血必净注射液( XBJI)对AECOPD者血清ET-1、ADM含量及肺功能的影响。方法将63例AECOPD者随机分为常规治疗组设为A组30例和XBJI治疗组设为B组33例及选择健康体检老年人设为C组27例。 A组常规治疗,B组常规治疗加用XBJI 60mg,静滴,2/d,疗程14天。测定治疗前后血清ET-1、ADM含量及FEV1%、FEV1/FVC的变化。正常对照组设为C组,不给药物治疗。结果 A、B两组治疗前血清ET-1、ADM含量明显高于C组,FEV1%、FEV1/FVC明显低于C组(均P<0．05)；A、B两组治疗后血清ET-1、ADM 含量及 FEV1%、FEV1/FVC 均明显改善( P <0．05), B 组治疗后血清 ET-1、ADM 含量及FEV1%、FEV1/FVC改善程度比A组明显(P<0．05)。结论 XBJI可降低血清ET-1、ADM含量,对ET-1与ADM有调节平衡作用,改善AECOPD患者血管舒缩功能和肺功能,对治疗AECOPD有显著疗效。
목적：연구혈필정주사액( XBJI)대AECOPD자혈청ET-1、ADM함량급폐공능적영향。방법장63례AECOPD자수궤분위상규치료조설위A조30례화XBJI치료조설위B조33례급선택건강체검노년인설위C조27례。 A조상규치료,B조상규치료가용XBJI 60mg,정적,2/d,료정14천。측정치료전후혈청ET-1、ADM함량급FEV1%、FEV1/FVC적변화。정상대조조설위C조,불급약물치료。결과 A、B량조치료전혈청ET-1、ADM함량명현고우C조,FEV1%、FEV1/FVC명현저우C조(균P<0．05)；A、B량조치료후혈청ET-1、ADM 함량급 FEV1%、FEV1/FVC 균명현개선( P <0．05), B 조치료후혈청 ET-1、ADM 함량급FEV1%、FEV1/FVC개선정도비A조명현(P<0．05)。결론 XBJI가강저혈청ET-1、ADM함량,대ET-1여ADM유조절평형작용,개선AECOPD환자혈관서축공능화폐공능,대치료AECOPD유현저료효。
Objective To investigate the effect of Xuebijing ( XBJ) injection on ET-1, ADM content and pulmonary function in patients with AEOPD. Methods 63 patients with AECOPD were randomly divided into the routine therapy group as the group A (30 cases) and the XBJ therapy group as the group B (33 cases). 27 healthy people were taken as the control group. The group B was injected with XBJ twice a day for 14 day on the basic of the routine therapy. The changes of serum ET-1, ADM content and FEV1%, FEV1/FVC were measured before and after the treatment. The group C wasn't given any drug treatment. Results Before the treatment, the levels of serum ET-1 and ADM were significantly higher in the group A and B than in the group C (P<0. 05), and the value of FEV1%and FEV1/FVC was obviously lower in the group A and B than in the group C (P<0. 05). After the treatment, the levels of serum ET-1, ADM, FEV1%, and FEV1/FVC were significantly better (P<0. 05), and the improvement of FEV1%, FEV1/FVC was more pronounced in the group B than in the group A ( P<0. 05 ) . Conclusion XBJ in-jection has significant effect to improve patients′vasomotor function and pulmonary function in AECOPD patients by reducing inflammation and the content of serum ET-1 and ADM.